Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 9
Submit an article Journal homepage
30
Views
5
CrossRef citations to date
0
Altmetric
Special Report

Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries

Gilbert R Kaufmann Basel Center for HIV Research, Division of Infectious Diseases, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland
,
Don Smith National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
,
Heiner C Bucher Basel Center for HIV Research, Division of Infectious Diseases, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland
,
Praphan Phanuphak Thai Red Cross, AIDS Research Centre, Chulalongkorn University, 1871 Rama IV Road Bangkok 10330, Thailand
,
Pedram P Sendi Institute for Medical Technology Assessment, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands
,
Edward K Mbidde Uganda Cancer Institute, PO Box 39, Kampala, Uganda
,
David A Cooper The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok 10330, Thailand
&
Manuel Battegay Basel Center for HIV Research, Division of Infectious Diseases, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. [email protected]
 show all
Pages 1303-1313 | Published online: 24 Feb 2005

Bibliography

  • DOUMATEY L, TRAORE R, KEROWENAN D, EONO P, AGUIRRE M: The Impact of AIDS counselling in Africa: the experience of Abidjan, Cote d'Ivoire. 12th World AIDS Conference, Geneva (1998): Abs. 24346.
  • CARPENTER CC, COOPER DA, FISCHL MA et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. "AMA (2000) 283:381–390.
  • CARR A, CHUAH J, HUDSON Jet al.: A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo 1 study. AIDS (2000) 14:1171–80.
  • MONTANER JS, REISS P, COOPER D et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. "AMA (1998) 279:930–937.
  • HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl.J Med. (1997) 337:725–733.
  • STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl. .1 Med. (1999) 341:1865–1873.
  • AUTRAN B, CARCELAIN G, LIT et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 277:112–116.
  • KELLEHER AD, CARR A, ZAUNDERS J, COOPER DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. Infect. Dis. (1996) 173:321–329.
  • EGGER M, HIRSCHEL B, FRANCIOLI P et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br. Med. "(1997) 315:1194–1199.
  • PALELLA FJ, JR, DELANEY KM, MOORMAN AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med. (1998) 338:853–860.
  • LEDERGERBER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 353:863–868.
  • GULICK RM, HU XJ, FISCUS SA et al.: Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J. Infect. Dis. (2000) 182:1375–1384.
  • KHANNA N, KLIMKAIT T, SCHIFFER V et al.: Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. AIDS (2000) 14:791–799.
  • FINZI D, BLANKS ON J, SILICIANO JD et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. (1999) 5:512–517.
  • CARR A, SAMARAS K, THORISDOTTIRA, KAUFMANN G, CHISHOLM D, COOPER D: Natural history, diagnosis and prediction of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet (1999) 353:2093–2099.
  • HO TT, CHAN KC, WONG KH, LEE SS: Abnormal fat distribution and use of protease inhibitors. Lancet (1998) 351:1736–1737.
  • MILLER KD, JONES E, YANOVSKI JA et al.: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet (1998) 351:871–875.
  • HENRY K, ZACKIN R, DUBE M, HAMMERS, CURRIER J: ACTG 5056: Metabolic status and cardiovascular disease risk for a cohort of HIV- 1-infected persons durably suppressed on an indinavir-containing regimen (ACTG 372A). 8th Conference on Retro viruses and Opportunistic Infections, Chicago, USA (2001) Abs. 656.
  • FRIEDLAND GH, WILLIAMS A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS (1999) 13\(Suppl. 1):S61–S72.
  • SEWANKAMBO N, GRAY R, NALUGODA F et al: Mortality associated with HIV infection in rural Rakai district, Uganda. XIII International AIDS Conference Durban, SA. (2000) Abs. TuOrC429.
  • BRAITSTEIN P, MONTANER J, SCHECHTER M et al.: Potential futures in Africa: to what extent could low-level anti-retroviral medication use curb the AIDS epidemic? XIII International AIDS Conference, Durban, SA. (2000) Abs. LbPp111.
  • CHANCHAROEN K, KUNANUSONT C, YIN D: Resource utilization of HIV/AIDS care in Thailand, a pilot study. XIII International AIDS Conference, Durban, SA. (2000) Abs. WeOrD567.
  • KONGSIN S, SIRINIRUND P, JIAMTON S, BOONTHUM A, WATTS C: The economic impact of HIV/AIDS on households in rural Thailand: The analysis of household coping strategies. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrD379.
  • GREENER R, JEFFERIS K, SIPHAMBE H: The impact of HIV/AIDS on poverty and inequality in Botswana. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrD326.
  • NANDAKUMAR A, SCHNEIDER P: Use of and expenditures on outpatient health care by a sample of HIV positive individuals in Rwanda. XIII International AIDS Conference, Durban, SA. (2000) Abs. WeOrD571.
  • SHAH S: Income generation and children'seducation are major issues, not HIV+ve status of husband. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoPeD2528.
  • FLOYD K, REID A, WILKINSON D, GILKS C: The economic impact of the HIV/ AIDS epidemic on the health sector in rural South Africa. XIII International AIDS Conference, Durban, SA. (2000) Abs. WeOrD461.
  • MORRIS C, CHEEVERS E, STEIN Z: Projected economic impact of HIV in the occupational setting in South Africa. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoPpE1065.
  • GREENER R, JEFFERIS K, SIPHAMBE H:The macroeconomic impact of HIV/AIDS in Botswana. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrD381.
  • FASSA M: HIV/AIDS impact assessment oncentral African republic and Cote d'Ivoire educational systems. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoPeE2956.
  • CAMPBELL C, WILLIAMS B: Beyond the biomedical and behavioural: towards an integrated approach to HIV prevention in the southern African mining industry. Soc. Sci. Med. (1999) 48:1625–1639.
  • KAHN J, SABA J, MARSEILLE E: The costs and benefits of employer-sponsored anti-retroviral drug provision. XIII International AIDS Conference, Durban, SA (2000) Abs. LBOr22.
  • BOZZETTE SA, JOYCE G, MCCAFFREY DF et al.: Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N EngI J. Med. (2001) 344:817–823.
  • •Refs 34, 36 also show that HAART is cost-effective in industrialised countries.
  • FREEDBERG KA, LOSINA E, WEINSTEIN MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl. J. Med. (2001) 344:824–831.
  • STEINBROOK R: Providing antiretroviral therapy for HIV infection. N Engl. J. Med. (2001) 344:844–846.
  • SENDI PP, BUCHER HC, HARR T et al.: Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 13:1115–1122.
  • BECK EJ, MINERS AH, TOLLEY K: The cost of HIV treatment and care. A global review. Eharmacoeconomics (2001) 19:13–39.
  • •Review on economic aspects of HIV infection.
  • SENDI PP, CRAIG BA, MEIER G et al: Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy.The Swiss HIV Cohort Study. J. Antlinicrob. Chemother. (1999) 44:811–817.
  • CHEQUER P, SUDO E, VITFRIA M, VELOSO V, CASTILHO E: The impact of anti-retroviral therapy in Brazil. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoPpE1066.
  • MEDA N, NDOYE I, M'BOUP S et al: Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? AIDS (1999) 13:1397-1405. Ref 42 also demonstrates that successful HIV prevention is possible in developing countries.
  • KAMALI A, CARPENTER LM, WHITWORTH JA et al.: Seven-year trends in HIV-1 infection rates, and changes in sexual behaviour, among adults in rural Uganda. AIDS (2000) 14:427–434.
  • PHOOLCHAROEN W: HIV/AIDS prevention in Thailand: success and challenges. Science (1998) 280:1873–1874.
  • BARYARAMA F, BUNNELL R, NAMWEBYA J et al: Declining HIV prevalence but continued transmission among youth seeking HIV testing in Uganda. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoPeC2419.
  • MARSEILLE E, KAHN JG, SABA J: Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS (1998) 12:939–948.
  • SODERLUND N, ZWI K, KINGHORN A, GRAY G: Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. Br. Med. J. (1999) 318:1650–1656.
  • NEWELL ML, DABISED F, TOLLEY K, WHYNES D: Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV. AIDS (1998) 12:1571–1580.
  • WOOD E, BRAITSTEIN P, MONTANER JS et al.: Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 355:2095–2100.
  • INTERNATIONAL AIDS SOCIETY: IAS position paper on prevention of HIV 1 mother-to-child transmission. International AIDS Society. AIDS (1999) 13:5–9.
  • WILSON D, CAWTHORNE P, FORD N, AONGSONWANG S: Global trade and access to medicines: AIDS treatments in Thailand. Lancet (1999) 354:1893–1895.
  • COCHRANE J: Narrowing the gap: accessto HIV treatments in developing countries. A pharmaceutical company's perspective. Med. Ethics (2000) 26:47-50; discussion 51–3.
  • BANTA D: Increase in global access to essential drugs sought. JAMA (2000) 283:321, 323.
  • AHMAD K: Brazil and USA at loggerheads over production of generic antiretrovirals. Lancet (2001) 357:453.
  • KRAISINTU K: Generic production of HIV-AIDS-related drugs in Thailand. XIII International AIDS Conference, Durban, SA. (2000) Abs. LbOr21.
  • UNGSEDHAPAND C, KROON ED, SUWANAGOOL S et al.: A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Acquir: Immune Defic. Syndr: (2001) 27:116–123.
  • GOTTLIEB S: Companies reduce prices for HIV drugs in developing countries. Bull. World Health Organ. (2000) 78:862.
  • MOSES S, PLUMMER FA, NGUGI EN, NAGELKERKE NJ, ANZALA AO, NDINYA-ACHOLA JO: Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS (1991) 5:407–411.
  • YODER C, BELSON M, CHUN T et al: Arandomized, controlled trial of intermittent versus continuoushighly active antiretroviral therapy (HAART). XIII International AIDS Conference, Durban, SA. (2000) Abs. LbOr11.
  • ZEITZ P: UNAIDS activity: debt-for-AIDS. XIII International AIDS Conference, Durban, SA. (2000) Abs. WePeE4878.
  • SICHONE M, LINTINI G, SIAMWIZA R, OFOSU-BARKO K, ZEITZ P: Scaling-up the HIV/AIDS response in Zambia through a multi-donor debt-for-development arrangement. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrE455.
  • WILSON D, CAWTHORNE P, T VSA: Access to anti-retroviral therapy in Thailand: What is the reality? XIII International AIDS Conference, Durban, SA. (2000) Abs. TuPpB1236.
  • NYAZEMA N: Access to and quality use of antiretrovirals, ARVs in Harare: A shared responsibility. XIII International AIDS Conference, Durban, SA. (2000) Abs. WePeD4582.
  • MUTEMI R, FORSYTHE S, ARTHUR G: Financial requirements of providing VCT throughout Kenya's health centres. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrC310.
  • WONG M, FISHER E, THOMPSON-BODKINS C, MERCIER B, KAPLOWITZ L: Enhanced cost effectiveness and improved clinical outcomes in expert physician managed HIV primary care in an inner city hospital HIV clinic. XIII International AIDS Conference, Durban, SA. (2000) Abs. MoOrB119.
  • LANIECE I, NDOYE I, SOW K et at.: Antiretroviral treatment initiative in Senegal: Results on treatment observence from a study conducted at the pharmacy. XIII International AIDS Conference, Durban, SA. (2000) Abs. ThPeB5011.
  • MERCHAN-HAMANN E, VALE M: Social and economic correlates of AIDS multi-drug therapy non-compliance in Brazil. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrB418.
  • MULINDWA M, KIYIMBA W, WANYANA S et al.: Treatment access and adherence to antiretrovirals (ARV) in HIV infected Ugandans. XIII International AIDS Conference, Durban, SA. (2000) Abs. TuOrB420.

Websites

  • http://www.unaids.org UNAIDS: Report on the global HIV/AIDS epidemic - December 2000.
  • •Global overview on the AIDS epidemic.
  • http://www.unaids.org UNAIDS: Report on the global HIV/AIDS epidemic - June 2000.
  • http://www.hivatis.org HIV/AIDS TREATMENT INFORMATION SERVICE: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
  • •Updated guidelines on the use of currently available antiretrovirals.
  • http://www.msf.org/advocacy/accessmed/ reports/ 192000/07/aidsconference/ MEDECINS SANS FRONTIERES: MSF calls for replication and expansion of successful efforts to reduce AIDS drug prices.
  • http://www.unaids.org/publications/ documents/sectors/workplace/hiv 1920001.pdf. UNAIDS: The business response to HIV/ AIDS: impact and lessons learned.• Highlights economic aspects of the AIDS epidemic.
  • http://www.unaids.org/hivaidsinfo/statistics/ june00/fact_sheets. UNAIDS: Epidemiological fact sheets by country.
  • •Summarises available epidemiological data on HIV/AIDS in developing countries.
  • http://www.medscape.com/reuters/prof/ 192000/03/03.17/pb03170c.html. ESIPISU M: Zambia steps up fight against AIDS. Reuters Medical News.
  • http://www.ilo.org/public/english/bureau/ inf/pr/ 192000/25.htm. INTERNATIONAL LABOUR ORGANIZATION: New ILO study warns of HIV/AIDS 'catastrophe' for workers and employers.
  • •Highlights the problems for businesses associated with the HIV/AIDS epidemic in developing countries.
  • http://www.wto.org/wto/english/tratop_e/ trips_e/paper_develop_w296_e.htm WORLD TRADE ORGANIZATION: TRIPS: A developing country group's paper.
  • http://www.aids.harvard.edu. HARVARD AIDS INSTITUTE: Groundbreaking blueprint calls for widespread availability of antiretroviral treatment to HIV-infected persons in poor countries.
  • •Discusses the feasibility of introducing HAART in developing countries and provides possible solutions and approaches.
  • http://www.unaids.org/whatsnew/others/ un_special/declaration2706_en.htm UNITED NATIONS: Declaration of commitment on HIV/AIDS.
  • http://www.cnn.com/HEALTH/9903/18/ aids.africa.02. US CENSUS BUREAU: Life expectancy in Africa cut short by AIDS.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.